22 February 2021
: Case report 
The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked Agammaglobulinemia
Unusual or unexpected effect of treatment, Rare coexistence of disease or pathology
Ali Almontasheri123AE*, Faisal Al-Husayni34E, Anas K. Alsuraihi4BF, Hanan Binyahib2F, Amr S. Albanna235EFDOI: 10.12659/AJCR.929447
Am J Case Rep 2021; 22:e929447
Table 1. Laboratory data concerning the diagnosis of X-linked agammaglobulinemia.
| Laboratory test | Result | Reference range |
|---|---|---|
| White blood count | 11.8 | 4.0–11.0×10/L |
| Hemoglobin | 13.7 | 11.5–16.5 g/dL |
| Platelet | 446 | 150–450×10/L |
| Neutrophils count | 5.30 | 2–7.5×10/L |
| Lymphocytes count | 4.11 | 1.5–4×10/L |
| CD3+ (T cells) | 98% | 67–76% |
| CD3+ CD4+ (T helpers) | 48% | 38–40% |
| CD3+ CD8+ (T suppressors) | 45% | 31–40% |
| CD19+ (B cells) | 0% | 11–16% |
| CD16+ CD56+ (natural killer cells) | 2% | 10–19% |
| CD3+ (T cells) | 4318.00 cells/mcL | 1100.00–1700.00 |
| CD3+ CD4+ (T helpers) | 2117.00 cells/mcL | 700.00–1100.00 cells/mcL |
| CD3+ CD8+ (T suppressors) | 2007.00 cells/mcL | 500.00–900.00 cells/mcL |
| CD19+ (B cells) | .0 cells/mcL | 200.0–400.0 cells/mcL |
| CD16+ CD56+ (natural killer cells) | 93.0 cells/mcL | 200.0–400.0 cells/mcL |
| Lymphocytes | 41.00% | 28.00–39.00% |
| CD4/CD8 ratio | 1.06 | 1.00–1.50 |
| Immunoglobulin G | 7.44 g/L | 6.6–15.3 g/L |
| Immunoglobulin E | <25.0 IU/mL | 25–449.7 IU/mL |
| Immunoglobulin A | <0.05 g/L | 0.5–2.9 g/L |
| Immunoglobulin M | <0.05 g/L | 0.4–1.5 g/L |
| CD – cluster of differentiation. * Patient is on regular intravenous immunoglobulin transfusion. | ||